Breaking Finance News

A report released today by Rodman & Renshaw about Aytu BioScience (OTC:AYTU) raises the target price to $9.00

Boasting a price of $3.35, Aytu BioScience (OTC:AYTU) traded 1.47% higher on the day. With the last stock price close down -29.79% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Aytu BioScience has recorded a 50-day average of $3.69 and a two hundred day average of $4.91. Volume of trade was up over the average, with 5,718 shares of AYTU changing hands over the typical 5,666

Aytu BioScience (OTC:AYTU) had its price target upped to $9.00 by Rodman & Renshaw in a report released 9/26/2016. The updated stock price target implies a possible upside of 1.69% from the company's most recent stock price close.

Recent Performance Chart

Aytu BioScience (OTC:AYTU)

Aytu BioScience has with a one year low of $3.01 and a one year high of $54.00 and has a total market value of $0.

More About Aytu BioScience (OTC:AYTU)

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.